Stephens Inc. AR boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,831 shares of the medical research company’s stock after purchasing an additional 91 shares during the period. Stephens Inc. AR’s holdings in Edwards Lifesciences Corporation were worth $926,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of EW. South Texas Money Management Ltd. raised its position in Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock worth $32,437,000 after acquiring an additional 211,119 shares during the period. Financial Counselors Inc. raised its position in Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock worth $1,283,000 after acquiring an additional 282 shares during the period. Westpac Banking Corp raised its position in Edwards Lifesciences Corporation by 13.5% in the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock worth $1,681,000 after acquiring an additional 1,691 shares during the period. Principal Financial Group Inc. raised its position in Edwards Lifesciences Corporation by 41.9% in the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock worth $55,086,000 after acquiring an additional 137,643 shares during the period. Finally, Ameriprise Financial Inc. raised its position in Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock worth $539,685,000 after acquiring an additional 850,168 shares during the period. Institutional investors own 82.36% of the company’s stock.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the firm’s stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 163,541 shares of company stock worth $18,712,719. 2.13% of the stock is owned by corporate insiders.

Several research analysts have weighed in on EW shares. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price target on the stock in a research report on Monday, May 22nd. Jefferies Group LLC set a $115.00 price objective on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a research report on Saturday, May 27th. Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, May 30th. Royal Bank Of Canada restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 30th. Finally, BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (EW) opened at 113.50 on Friday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company has a market cap of $23.97 billion, a price-to-earnings ratio of 34.43 and a beta of 0.64. The stock has a 50 day moving average of $113.99 and a 200 day moving average of $108.88.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.76 earnings per share. Analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/17/edwards-lifesciences-corporation-ew-shares-bought-by-stephens-inc-ar.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.